We’re in San Sebastián 🇪🇸 with one of the top VCs in Europe, Christina Takke from V-Bio Ventures. We talk about her path to get to the top and the benefits of gender diversity for both investing and European biotech as a whole. We also talk about her investment in Argenx when it was only three employees and the venture creation had dropped since 2022. 🔗 LINKS MENTIONED - Lean years for company creation in Europe? - BioVox, Sep 2023 - https://biovox.eu/lean-years-for-company-creation-in-europe/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/christina-takke-v-bio-ventures/ 💸 DONATE We welcome donations from individuals and businesses to support our more content creation: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:02:03] Top VC woman in biotech [00:08:36] European background [00:13:49] Investing in Argenx at the start [00:20:26] V-Bio story [00:25:09] Tech transfer [00:35:44] Company creation drop [00:42:39] Thanks for listening